| MeSH term | MeSH ID | Detail |
|---|---|---|
| Gram-Negative Bacterial Infections | D016905 | 16 associated lipids |
| Angiomatosis, Bacillary | D016917 | 2 associated lipids |
| Meningitis, Bacterial | D016920 | 6 associated lipids |
| Common Variable Immunodeficiency | D017074 | 4 associated lipids |
| AIDS-Related Opportunistic Infections | D017088 | 9 associated lipids |
| IgA Deficiency | D017098 | 2 associated lipids |
| Liver Failure, Acute | D017114 | 11 associated lipids |
| Skin Diseases, Bacterial | D017192 | 8 associated lipids |
| Dermatitis, Phototoxic | D017484 | 4 associated lipids |
| Pityriasis Rosea | D017515 | 3 associated lipids |
| Cutaneous Fistula | D017577 | 1 associated lipids |
| Kleine-Levin Syndrome | D017593 | 1 associated lipids |
| Periodontal Attachment Loss | D017622 | 7 associated lipids |
| Soft Tissue Injuries | D017695 | 2 associated lipids |
| Community-Acquired Infections | D017714 | 8 associated lipids |
| Cytomegalovirus Retinitis | D017726 | 2 associated lipids |
| Tuberculosis, Multidrug-Resistant | D018088 | 6 associated lipids |
| Cardiovascular Abnormalities | D018376 | 2 associated lipids |
| Pneumonia, Bacterial | D018410 | 16 associated lipids |
| Soft Tissue Infections | D018461 | 2 associated lipids |
| Ventricular Dysfunction, Left | D018487 | 33 associated lipids |
| Cryptogenic Organizing Pneumonia | D018549 | 3 associated lipids |
| Carcinoma, Lewis Lung | D018827 | 22 associated lipids |
| Gingival Overgrowth | D019214 | 7 associated lipids |
| Tooth, Nonvital | D019553 | 2 associated lipids |
| alpha 1-Antitrypsin Deficiency | D019896 | 3 associated lipids |
| Genetic Predisposition to Disease | D020022 | 24 associated lipids |
| Neurotoxicity Syndromes | D020258 | 34 associated lipids |
| Central Nervous System Protozoal Infections | D020808 | 3 associated lipids |
| Epilepsy, Partial, Motor | D020938 | 1 associated lipids |
| Chlamydophila Infections | D023521 | 4 associated lipids |
| Desulfovibrionaceae Infections | D045824 | 5 associated lipids |
| Renal Insufficiency | D051437 | 8 associated lipids |
| Immune Reconstitution Inflammatory Syndrome | D054019 | 1 associated lipids |
| Buruli Ulcer | D054312 | 1 associated lipids |
| Extensively Drug-Resistant Tuberculosis | D054908 | 1 associated lipids |
| Leprosy, Paucibacillary | D056005 | 2 associated lipids |
| Upper Extremity Deep Vein Thrombosis | D056824 | 1 associated lipids |
| Acute Kidney Injury | D058186 | 34 associated lipids |
| Plaque, Atherosclerotic | D058226 | 7 associated lipids |
| Sacroiliitis | D058566 | 1 associated lipids |
| Chlamydial Pneumonia | D061387 | 2 associated lipids |
clarithromycin
clarithromycin is a lipid of Polyketides (PK) class. Clarithromycin is associated with abnormalities such as Helicobacter Pylori Infection, Infection, Coinfection, Gastritis and Peptic Ulcer. The involved functions are known as Point Mutation, Increased Sensitivy, Bacterial resistance, urease activity and Mutation. Clarithromycin often locates in Blood, Gastric mucosa, Biopsy sample, Respiratory System and Entire gastrointestinal tract. The associated genes with clarithromycin are Genes, rRNA, rRNA Operon, Genome, HM13 gene and GDF15 gene. The related lipids are 9,11-linoleic acid, Steroids, Lysophosphatidylcholines, Lipopolysaccharides and 4-hydroxycholesterol. The related experimental models are Mouse Model, Knock-out and Experimental Pneumococcal Meningitis.
Cross Reference
Introduction
To understand associated biological information of clarithromycin, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with clarithromycin?
clarithromycin is suspected in Infection, Helicobacter Pylori Infection, Pneumonia, Respiratory Tract Infections, PARKINSON DISEASE, LATE-ONSET, Community acquired pneumonia and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
- Antimicrob. Agents Chemother. (63)
- J. Antimicrob. Chemother. (56)
- J. Clin. Microbiol. (39)
- Others (258)
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with clarithromycin
PubChem Associated disorders and diseases
What pathways are associated with clarithromycin
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with clarithromycin?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
- J. Antimicrob. Chemother. (25)
- Antimicrob. Agents Chemother. (20)
- J. Clin. Microbiol. (9)
- Others (66)
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with clarithromycin?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with clarithromycin?
Related references are published most in these journals:
- Antimicrob. Agents Chemother. (5)
- Drug Metab. Dispos. (1)
- FEMS Immunol. Med. Microbiol. (1)
- Others (5)
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What genes are associated with clarithromycin?
Related references are published most in these journals:
- J. Antimicrob. Chemother. (20)
- Antimicrob. Agents Chemother. (17)
- J. Clin. Microbiol. (13)
- Others (57)
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with clarithromycin?
Mouse Model
Mouse Model are used in the study 'Inflammation provoked by Mycoplasma pneumoniae extract: implications for combination treatment with clarithromycin and dexamethasone.' (Hirao S et al., 2011), Mouse Model are used in the study 'Tolerance and pharmacokinetic interactions of rifabutin and clarithromycin in human immunodeficiency virus-infected volunteers.' (Hafner R et al., 1998), Mouse Model are used in the study 'Clarithromycin attenuates mastectomy-induced acute inflammatory response.' (Chow LW et al., 2000) and Mouse Model are used in the study 'In vitro and in vivo influence of adjunct clarithromycin on the treatment of mucoid Pseudomonas aeruginosa.' (Bui KQ et al., 2000).
Knock-out
Knock-out are used in the study 'Intrinsic macrolide resistance in Mycobacterium smegmatis is conferred by a novel erm gene, erm(38).' (Nash KA, 2003).
Experimental Pneumococcal Meningitis
Experimental Pneumococcal Meningitis are used in the study 'Failure of treatment for chronic Mycobacterium abscessus meningitis despite adequate clarithromycin levels in cerebrospinal fluid.' (Maniu CV et al., 2001).
Related references are published most in these journals:
| Model | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
NCBI Entrez Crosslinks
All references with clarithromycin
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Morikawa K et al. | Modulatory effect of antibiotics on cytokine production by human monocytes in vitro. | 1996 | Antimicrob. Agents Chemother. | pmid:8726002 |
| Arain TM et al. | Bioluminescence screening in vitro (Bio-Siv) assays for high-volume antimycobacterial drug discovery. | 1996 | Antimicrob. Agents Chemother. | pmid:8726034 |
| Lounis N et al. | ATP synthase inhibition of Mycobacterium avium is not bactericidal. | 2009 | Antimicrob. Agents Chemother. | pmid:19738016 |
| Giacometti A et al. | In vitro activity and killing effect of uperin 3.6 against gram-positive cocci isolated from immunocompromised patients. | 2005 | Antimicrob. Agents Chemother. | pmid:16127075 |
| Peric M et al. | Effects of an efflux mechanism and ribosomal mutations on macrolide susceptibility of Haemophilus influenzae clinical isolates. | 2003 | Antimicrob. Agents Chemother. | pmid:12604536 |
| Kim JM et al. | Distribution of antibiotic MICs for Helicobacter pylori strains over a 16-year period in patients from Seoul, South Korea. | 2004 | Antimicrob. Agents Chemother. | pmid:15561865 |
| Fish DN et al. | Penetration of clarithromycin into lung tissues from patients undergoing lung resection. | 1994 | Antimicrob. Agents Chemother. | pmid:8031063 |
| Hirschl AM et al. | In vitro activities of linezolid alone and in combination with amoxicillin, clarithromycin, and metronidazole against Helicobacter pylori. | 2000 | Antimicrob. Agents Chemother. | pmid:10858365 |
| Gustavson LE et al. | Effect of omeprazole on concentrations of clarithromycin in plasma and gastric tissue at steady state. | 1995 | Antimicrob. Agents Chemother. | pmid:8540719 |
| Endo H et al. | Effects of clarithromycin and amoxicillin on gastric emptying in rats. | 2002 | Antimicrob. Agents Chemother. | pmid:12234874 |
| Roblin PM et al. | In vitro activity of CEM-101, a new fluoroketolide antibiotic, against Chlamydia trachomatis and Chlamydia (Chlamydophila) pneumoniae. | 2010 | Antimicrob. Agents Chemother. | pmid:20038627 |
| Hammerschlag MR et al. | In vitro activities of azithromycin, clarithromycin, L-ofloxacin, and other antibiotics against Chlamydia pneumoniae. | 1992 | Antimicrob. Agents Chemother. | pmid:1324650 |
| Nagashima A et al. | Clarithromycin Suppresses Chloride Channel Accessory 1 and Inhibits Interleukin-13-Induced Goblet Cell Hyperplasia in Human Bronchial Epithelial Cells. | 2016 | Antimicrob. Agents Chemother. | pmid:27550358 |
| Kosowska-Shick K et al. | Multistep resistance selection and postantibiotic-effect studies of the antipneumococcal activity of LBM415 compared to other agents. | 2007 | Antimicrob. Agents Chemother. | pmid:17116666 |
| Riska PF et al. | Genetic and culture-based approaches for detecting macrolide resistance in Chlamydia pneumoniae. | 2004 | Antimicrob. Agents Chemother. | pmid:15328134 |
| Perronne C et al. | Activities of clarithromycin, sulfisoxazole, and rifabutin against Mycobacterium avium complex multiplication within human macrophages. | 1990 | Antimicrob. Agents Chemother. | pmid:2171421 |
| Goldstein EJ et al. | Activities of telithromycin (HMR 3647, RU 66647) compared to those of erythromycin, azithromycin, clarithromycin, roxithromycin, and other antimicrobial agents against unusual anaerobes. | 1999 | Antimicrob. Agents Chemother. | pmid:10543769 |
| Fernández-Roblas R et al. | In vitro susceptibilities of rapidly growing mycobacteria to telithromycin (HMR 3647) and seven other antimicrobials. | 2000 | Antimicrob. Agents Chemother. | pmid:10602744 |
| Jung R et al. | Postantibiotic effects and bactericidal activities of clarithromycin-14-hydroxy-clarithromycin, versus those of amoxicillin-clavulanate, against anaerobes. | 2000 | Antimicrob. Agents Chemother. | pmid:10681358 |
| Sassa K et al. | Therapeutic effect of clarithromycin on a transplanted tumor in rats. | 1999 | Antimicrob. Agents Chemother. | pmid:9869567 |
| Meier A et al. | Identification of mutations in 23S rRNA gene of clarithromycin-resistant Mycobacterium intracellulare. | 1994 | Antimicrob. Agents Chemother. | pmid:8192472 |
| Kohno Y et al. | Autobacteriographic studies of clarithromycin and erythromycin in mice. | 1990 | Antimicrob. Agents Chemother. | pmid:2140497 |
| Loreto ES et al. | New insights into the in vitro susceptibility of Pythium insidiosum. | 2014 | Antimicrob. Agents Chemother. | pmid:25223997 |
| Chan GP et al. | Clinical trial of clarithromycin for lepromatous leprosy. | 1994 | Antimicrob. Agents Chemother. | pmid:8203847 |
| Clark C et al. | In vitro selection of resistance in Haemophilus influenzae by amoxicillin-clavulanate, cefpodoxime, cefprozil, azithromycin, and clarithromycin. | 2002 | Antimicrob. Agents Chemother. | pmid:12183253 |
| Hardy DJ et al. | Enhancement of the in vitro and in vivo activities of clarithromycin against Haemophilus influenzae by 14-hydroxy-clarithromycin, its major metabolite in humans. | 1990 | Antimicrob. Agents Chemother. | pmid:2143642 |
| Hunt Gerardo S et al. | Comparison of Etest to broth microdilution method for testing Streptococcus pneumoniae susceptibility to levofloxacin and three macrolides. | 1996 | Antimicrob. Agents Chemother. | pmid:8891154 |
| Lemaire S et al. | Cellular accumulation and pharmacodynamic evaluation of the intracellular activity of CEM-101, a novel fluoroketolide, against Staphylococcus aureus, Listeria monocytogenes, and Legionella pneumophila in human THP-1 macrophages. | 2009 | Antimicrob. Agents Chemother. | pmid:19564365 |
| Tamaoki J et al. | Effect of clarithromycin on sputum production and its rheological properties in chronic respiratory tract infections. | 1995 | Antimicrob. Agents Chemother. | pmid:7486901 |
| Alvarez A et al. | Antimicrobial susceptibility and mutations involved in clarithromycin resistance in Helicobacter pylori isolates from patients in the western central region of Colombia. | 2009 | Antimicrob. Agents Chemother. | pmid:19546360 |
| Vance E et al. | Pharmacokinetics of clarithromycin and zidovudine in patients with AIDS. | 1995 | Antimicrob. Agents Chemother. | pmid:7574530 |
| Koh WJ et al. | Treatment of refractory Mycobacterium avium complex lung disease with a moxifloxacin-containing regimen. | 2013 | Antimicrob. Agents Chemother. | pmid:23478956 |
| van Zanten SJ et al. | Gastric transitional zones, areas where Helicobacter treatment fails: results of a treatment trial using the Sydney strain mouse model. | 2003 | Antimicrob. Agents Chemother. | pmid:12821476 |
| Zhou Z et al. | Macrolide-resistant Mycoplasma pneumoniae in adults in Zhejiang, China. | 2015 | Antimicrob. Agents Chemother. | pmid:25451048 |
| Gikas A et al. | In vitro susceptibility of Coxiella burnetii to trovafloxacin in comparison with susceptibilities to pefloxacin, ciprofloxacin, ofloxacin, doxycycline, and clarithromycin. | 1998 | Antimicrob. Agents Chemother. | pmid:9756789 |
| Debets-Ossenkopp YJ et al. | Explaining the bias in the 23S rRNA gene mutations associated with clarithromycin resistance in clinical isolates of Helicobacter pylori. | 1998 | Antimicrob. Agents Chemother. | pmid:9756790 |
| Kuo CC et al. | In vitro activities of azithromycin, clarithromycin, and other antibiotics against Chlamydia pneumoniae. | 1996 | Antimicrob. Agents Chemother. | pmid:8913488 |
| Hogan PA and Sheehan DJ | Macrolide susceptibility and beta-lactamase production among haemophilus influenzae isolates in the United States, 1996-1997. | 1998 | Antimicrob. Agents Chemother. | pmid:9835536 |
| Diacon AH et al. | Randomized pilot trial of eight weeks of bedaquiline (TMC207) treatment for multidrug-resistant tuberculosis: long-term outcome, tolerability, and effect on emergence of drug resistance. | 2012 | Antimicrob. Agents Chemother. | pmid:22391540 |
| Mor N and Heifets L | MICs and MBCs of clarithromycin against Mycobacterium avium within human macrophages. | 1993 | Antimicrob. Agents Chemother. | pmid:8431006 |
| Tomioka H et al. | In vitro antimicrobial activity of benzoxazinorifamycin, KRM-1648, against Mycobacterium avium complex, determined by the radiometric method. | 1993 | Antimicrob. Agents Chemother. | pmid:8431020 |
| Rouse MS et al. | Efficacy of azithromycin or clarithromycin for prophylaxis of viridans group streptococcus experimental endocarditis. | 1997 | Antimicrob. Agents Chemother. | pmid:9257739 |
| Pryjma M et al. | Antagonism between Front-Line Antibiotics Clarithromycin and Amikacin in the Treatment of Mycobacterium abscessus Infections Is Mediated by the Gene. | 2017 | Antimicrob. Agents Chemother. | pmid:28874379 |
| Bolhuis MS et al. | Clinical validation of the analysis of linezolid and clarithromycin in oral fluid of patients with multidrug-resistant tuberculosis. | 2013 | Antimicrob. Agents Chemother. | pmid:23689722 |
| Spaniol V et al. | Moraxella catarrhalis AcrAB-OprM efflux pump contributes to antimicrobial resistance and is enhanced during cold shock response. | 2015 | Antimicrob. Agents Chemother. | pmid:25583725 |
| Conte JE et al. | Intrapulmonary pharmacokinetics of clarithromycin and of erythromycin. | 1995 | Antimicrob. Agents Chemother. | pmid:7726492 |
| Visalli MA et al. | Susceptibility of penicillin-susceptible and -resistant pneumococci to dirithromycin compared with susceptibilities to erythromycin, azithromycin, clarithromycin, roxithromycin, and clindamycin. | 1997 | Antimicrob. Agents Chemother. | pmid:9303375 |
| Ednie LM et al. | Comparative antianaerobic activities of the ketolides HMR 3647 (RU 66647) and HMR 3004 (RU 64004). | 1997 | Antimicrob. Agents Chemother. | pmid:9303406 |
| Seyama S et al. | Clarithromycin Resistance Mechanisms of Epidemic β-Lactamase-Nonproducing Ampicillin-Resistant Haemophilus influenzae Strains in Japan. | 2016 | Antimicrob. Agents Chemother. | pmid:26953210 |
| Berry V et al. | Bacteriological efficacies of three macrolides compared with those of amoxicillin-clavulanate against Streptococcus pneumoniae and Haemophilus influenzae. | 1998 | Antimicrob. Agents Chemother. | pmid:9835514 |
| Lazard T et al. | Efficacy of granulocyte colony-stimulating factor and RU-40555 in combination with clarithromycin against Mycobacterium avium complex infection in C57BL/6 mice. | 1993 | Antimicrob. Agents Chemother. | pmid:7684213 |
| Emori M et al. | Therapeutic efficacy of the benzoxazinorifamycin KRM-1648 against experimental Mycobacterium avium infection induced in rabbits. | 1993 | Antimicrob. Agents Chemother. | pmid:7684214 |
| Chu SY et al. | Absolute bioavailability of clarithromycin after oral administration in humans. | 1992 | Antimicrob. Agents Chemother. | pmid:1387301 |
| Yajko DM et al. | Comparison of the intracellular activities of clarithromycin and erythromycin against Mycobacterium avium complex strains in J774 cells and in alveolar macrophages from human immunodeficiency virus type 1-infected individuals. | 1992 | Antimicrob. Agents Chemother. | pmid:1387302 |
| de Lalla F et al. | Clarithromycin-ciprofloxacin-amikacin for therapy of Mycobacterium avium-Mycobacterium intracellulare bacteremia in patients with AIDS. | 1992 | Antimicrob. Agents Chemother. | pmid:1387303 |
| Zhanel GG et al. | Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006. | 2008 | Antimicrob. Agents Chemother. | pmid:18285482 |
| Rastogi N and Labrousse V | Extracellular and intracellular activities of clarithromycin used alone and in association with ethambutol and rifampin against Mycobacterium avium complex. | 1991 | Antimicrob. Agents Chemother. | pmid:1828135 |
| Hardy RD et al. | Antimicrobial and immunologic activities of clarithromycin in a murine model of Mycoplasma pneumoniae-induced pneumonia. | 2003 | Antimicrob. Agents Chemother. | pmid:12709330 |
| Tomioka H et al. | Intramacrophage passage of Mycobacterium tuberculosis and M. avium complex alters the drug susceptibilities of the organisms as determined by intracellular susceptibility testing using macrophages and type II alveolar epithelial cells. | 2002 | Antimicrob. Agents Chemother. | pmid:11796367 |
| Naik S and Ruck R | In vitro activities of several new macrolide antibiotics against Mycobacterium avium complex. | 1989 | Antimicrob. Agents Chemother. | pmid:2817858 |
| Perronne C et al. | Activities of sparfloxacin, azithromycin, temafloxacin, and rifapentine compared with that of clarithromycin against multiplication of Mycobacterium avium complex within human macrophages. | 1991 | Antimicrob. Agents Chemother. | pmid:1656860 |
| Phillips RO et al. | Reply to "compliance with antimicrobial therapy for buruli ulcer". | 2014 | Antimicrob. Agents Chemother. | pmid:25225343 |
| Klis S et al. | Compliance with antimicrobial therapy for buruli ulcer. | 2014 | Antimicrob. Agents Chemother. | pmid:25225342 |
| Fish DN and Abraham E | Pharmacokinetics of a clarithromycin suspension administered via nasogastric tube to seriously ill patients. | 1999 | Antimicrob. Agents Chemother. | pmid:10223952 |
| Truffot-Pernot C et al. | Effect of pH on the in vitro potency of clarithromycin against Mycobacterium avium complex. | 1991 | Antimicrob. Agents Chemother. | pmid:1834015 |
| Tsay FW et al. | A Randomized Controlled Trial Shows that both 14-Day Hybrid and Bismuth Quadruple Therapies Cure Most Patients with Helicobacter pylori Infection in Populations with Moderate Antibiotic Resistance. | 2017 | Antimicrob. Agents Chemother. | pmid:28807915 |
| Klemens SP et al. | Activity of clarithromycin against Mycobacterium avium complex infection in beige mice. | 1992 | Antimicrob. Agents Chemother. | pmid:1336945 |
| Vaara M et al. | A novel polymyxin derivative that lacks the fatty acid tail and carries only three positive charges has strong synergism with agents excluded by the intact outer membrane. | 2010 | Antimicrob. Agents Chemother. | pmid:20479195 |
| Hsu PI et al. | Randomized controlled trial comparing 7-day triple, 10-day sequential, and 7-day concomitant therapies for Helicobacter pylori infection. | 2014 | Antimicrob. Agents Chemother. | pmid:25070099 |
| Cheng KL et al. | Effect of grapefruit juice on clarithromycin pharmacokinetics. | 1998 | Antimicrob. Agents Chemother. | pmid:9559810 |
| Secka O et al. | Antimicrobial susceptibility and resistance patterns among Helicobacter pylori strains from The Gambia, West Africa. | 2013 | Antimicrob. Agents Chemother. | pmid:23263004 |
| Ji B et al. | Bactericidal activity of single dose of clarithromycin plus minocycline, with or without ofloxacin, against Mycobacterium leprae in patients. | 1996 | Antimicrob. Agents Chemother. | pmid:8878595 |
| Hafner R et al. | Tolerance and pharmacokinetic interactions of rifabutin and clarithromycin in human immunodeficiency virus-infected volunteers. | 1998 | Antimicrob. Agents Chemother. | pmid:9517944 |
| Fattorini L et al. | Activities of isoniazid alone and in combination with other drugs against Mycobacterium avium infection in beige mice. | 1998 | Antimicrob. Agents Chemother. | pmid:9517960 |
| Heifets L | Susceptibility testing of Mycobacterium avium complex isolates. | 1996 | Antimicrob. Agents Chemother. | pmid:8843278 |
| Alper CM et al. | Efficacy of clarithromycin treatment of acute otitis media caused by infection with penicillin-susceptible, -intermediate, and -resistant Streptococcus pneumoniae in the chinchilla. | 1996 | Antimicrob. Agents Chemother. | pmid:8843299 |
| Carr RA et al. | Steady-state pharmacokinetics and electrocardiographic pharmacodynamics of clarithromycin and loratadine after individual or concomitant administration. | 1998 | Antimicrob. Agents Chemother. | pmid:9593146 |
| Sörberg M et al. | Risk of development of in vitro resistance to amoxicillin, clarithromycin, and metronidazole in Helicobacter pylori. | 1998 | Antimicrob. Agents Chemother. | pmid:9593154 |
| Mougari F et al. | Selection of Resistance to Clarithromycin in Mycobacterium abscessus Subspecies. | 2017 | Antimicrob. Agents Chemother. | pmid:27799212 |
| Yamaguchi H et al. | Chlamydia pneumoniae resists antibiotics in lymphocytes. | 2003 | Antimicrob. Agents Chemother. | pmid:12760877 |
| Ji B et al. | Bactericidal activities of combinations of new drugs against Mycobacterium leprae in nude mice. | 1996 | Antimicrob. Agents Chemother. | pmid:8834886 |
| Kutlin A et al. | Effect of prolonged treatment with azithromycin, clarithromycin, or levofloxacin on Chlamydia pneumoniae in a continuous-infection Model. | 2002 | Antimicrob. Agents Chemother. | pmid:11796350 |
| Yamamoto T et al. | Activity of KRM-1648 alone or in combination with both ethambutol and kanamycin or clarithromycin against Mycobacterium intracellulare infections in beige mice. | 1996 | Antimicrob. Agents Chemother. | pmid:8834892 |
| Jacks SS et al. | In vitro susceptibilities of Rhodococcus equi and other common equine pathogens to azithromycin, clarithromycin, and 20 other antimicrobials. | 2003 | Antimicrob. Agents Chemother. | pmid:12709351 |
| Ji B et al. | How effective is KRM-1648 in treatment of disseminated Mycobacterium avium complex infections in beige mice? | 1996 | Antimicrob. Agents Chemother. | pmid:8834894 |
| Dattwyler RJ et al. | Clarithromycin in treatment of early Lyme disease: a pilot study. | 1996 | Antimicrob. Agents Chemother. | pmid:8834900 |
| Versalovic J et al. | Mutations in 23S rRNA are associated with clarithromycin resistance in Helicobacter pylori. | 1996 | Antimicrob. Agents Chemother. | pmid:8834903 |
| Alffenaar JW et al. | Pharmacokinetics of rifampin and clarithromycin in patients treated for Mycobacterium ulcerans infection. | 2010 | Antimicrob. Agents Chemother. | pmid:20585115 |
| Wallace RJ et al. | Genetic basis for clarithromycin resistance among isolates of Mycobacterium chelonae and Mycobacterium abscessus. | 1996 | Antimicrob. Agents Chemother. | pmid:8807061 |
| Kishii K et al. | In vitro activity of tebipenem, a new oral carbapenem antibiotic, against beta-lactamase-nonproducing, ampicillin-resistant Haemophilus influenzae. | 2010 | Antimicrob. Agents Chemother. | pmid:20585130 |
| Gillum JG et al. | Effect of combination therapy with ciprofloxacin and clarithromycin on theophylline pharmacokinetics in healthy volunteers. | 1996 | Antimicrob. Agents Chemother. | pmid:8807068 |
| Hoffman HL et al. | Influence of macrolide susceptibility on efficacies of clarithromycin and azithromycin against Streptococcus pneumoniae in a murine lung infection model. | 2003 | Antimicrob. Agents Chemother. | pmid:12543686 |
| Lounis N et al. | Efficacies of clarithromycin regimens against Mycobacterium xenopi in mice. | 2001 | Antimicrob. Agents Chemother. | pmid:11600387 |
| Gikas A et al. | In vitro susceptibility of Coxiella burnetii to linezolid in comparison with its susceptibilities to quinolones, doxycycline, and clarithromycin. | 2001 | Antimicrob. Agents Chemother. | pmid:11600400 |
| Meyer JM et al. | In vitro synergy testing of clarithromycin and 14-hydroxyclarithromycin with amoxicillin or bismuth subsalicylate against Helicobacter pylori. | 1997 | Antimicrob. Agents Chemother. | pmid:9210696 |
| Chen D et al. | Phenotypic and Molecular Antimicrobial Susceptibility of Helicobacter pylori. | 2017 | Antimicrob. Agents Chemother. | pmid:28167563 |
| Fontana C et al. | New site of modification of 23S rRNA associated with clarithromycin resistance of Helicobacter pylori clinical isolates. | 2002 | Antimicrob. Agents Chemother. | pmid:12435674 |
| Noreddin AM et al. | Pharmacodynamic modeling of clarithromycin against macrolide-resistant [PCR-positive mef(A) or erm(B)] Streptococcus pneumoniae simulating clinically achievable serum and epithelial lining fluid free-drug concentrations. | 2002 | Antimicrob. Agents Chemother. | pmid:12435719 |
| Obregón-Henao A et al. | Susceptibility of Mycobacterium abscessus to antimycobacterial drugs in preclinical models. | 2015 | Antimicrob. Agents Chemother. | pmid:26303795 |
| Piccolomini R et al. | Bacteriostatic and bactericidal in vitro activities of clarithromycin and erythromycin against periodontopathic Actinobacillus actinomycetemcomitans. | 1998 | Antimicrob. Agents Chemother. | pmid:9797240 |